The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | CureCloud: liquid biopsy sequencing for multiple myeloma
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the direct-to-patient Multiple Myeloma Research Foundation (MMRF) CureCloud Research Initiative. This study has developed a clinical-grade next-generation liquid biopsy sequencing platform, which allows for minimally invasive monitoring of multiple myeloma from home. Genomic reports are provided to the patients through the CureCloud platform and can be used for clinical care and trial identification. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
